ChristopherGasinkMD

Physician

Dr. Gasink is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
3400 Spruce St
Fl 3
Philadelphia, PA 19104
Phone+1 215-349-8222

Fax+1 215-615-0500

University of Pennsylvania Health SystemFellowship, Gastroenterology, 2001 - 2004
University of Pennsylvania Health SystemResidency, Internal Medicine, 1998 - 2001
University of Virginia School of MedicineClass of 1998

PubMed

105 citations
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial.
William J. Sandborn, Rory Rebuck, Yuhua Wang, Bin Zou, Omoniyi J. Adedokun
Clinical Gastroenterology and Hepatology. 2021-02-19
129 citations
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
Stephen B. Hanauer, William J. Sandborn, Brian G. Feagan, Christopher Gasink, Douglas Jacobstein
Journal of Crohn's & Colitis. 2020-01-01
118 citations
Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis
Jean-Frederic Colombel, Omoniyi J. Adedokun, Christopher Gasink, Long Long Gao, Freddy Cornillie
Clinical Gastroenterology and Hepatology. 2019-07-01

JnJ Tremfya Receives USFDA Approval for Adults with Moderately to Severely Active Ulcerative ColitisSeptember 11th, 2024
TREMFYA® (Guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis, Strengthening Johnson & Johnson's Leadership in Inflammatory Bowel DiseaseSeptember 11th, 2024
TREMFYA® (Guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis, Strengthening Johnson & Johnson's Leadership in Inflammatory Bowel DiseaseSeptember 11th, 2024
Join now to see all